Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19

Bundgaard et al., NCT04335136, APN01-COVID-19, NCT04335136, Dec 2020
RCT 181 hospitalized COVID-19 patients showing no significant improvement with alunacedase alfa.
OutcomeImprovementEffect · pTreatmentControl
risk of death 31.5% higher · RR 1.31 · p = 0.61 31.5% higherRR 1.31p = 0.61 9 of 88 (10.2%) 7 of 90 (7.8%) treatment 9 of 88 (10.2%), control 7 of 90 (7.8%)day 28
risk of mechanical ventilation 23.3% lower · RR 0.77 · p = 0.64 23.3% lowerRR 0.77p = 0.64 9 of 88 (10.2%) 12 of 90 (13.3%) treatment 9 of 88 (10.2%), control 12 of 90 (13.3%)NNT 32day 28

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Bundgaard et al., 26 Dec 2020, Double Blind Randomized Controlled Trial, placebo-controlled, Austria, preprint, 1 author, trial NCT04335136 (history) (APN01-COVID-19). Contact: romana.gugenberger@apeiron-biologics.com.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 Austria Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia Austria favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 Austria Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Austria favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective